{"prompt": "[\"Appendix 1: Schedule of Activities (cont'd)\", 'End of', 'Treatment Continuation', 'Follow-up', 'Screening', 'Baseline', 'Treatment Cross-over Period', 'Treatment', 'Period [a]', 'Period [c]', 'Visit [b]', '15', '11', 'Study Cycle', '1', '2', '3', '4', '5', '6', '7', '(or last', '[d]', 'treatment', 'cycle) [e]', ' 28 days', 'Day', '-28 to -1', '-7 to -1', '1', '1', '1', '1', '1', '1', '1', '1', '1', 'from last', 'study dose', 'Investigator assessment to', 'exclude residual/recurrent', 'X', 'or metastatic disease as', 'per institutional practice', 'Clinical breast examination', 'X', 'x', 'X', 'X', 'X', 'X', 'X', '[I]', '[I]', 'Electrocardiogram', 'X', 'LVEF [m]', 'X', 'X', 'X', 'X [m]', 'Haematology / limited', 'X', 'X', 'X', 'X', 'X', 'biochemistry [n]', 'Pregnancy test [o]', 'X', '[o]', 'X [o]', '[o]', 'X', 'x[o]', 'Adverse-events- [p]', '*', '*', '*', 'Adverse events [p]', 'x', 'x', 'Collected on an ongoing basis', 'x [p]', 'Concomitant medication [q]', '*', '*', '*', '*[[]]', 'Concomitant medication [q]', 'x', 'Collected on an ongoing basis', 'x [q]', 'PPQ [r]', 'Arm', 'Arm', 'TASQ-IV', 'A', 'B', 'only', 'only', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '96 / Protocol MO40628, Version 12'][\"Appendix 1: Schedule of Activities (cont'd)\", 'End of', 'Treatment Continuation', 'Follow-up', 'Screening', 'Baseline', 'Treatment Cross-over Period', 'Treatment', 'Period [a]', 'Period [c]', 'Visit [b]', '15', '11', 'Study Cycle', '1', '2', '3', '4', '5', '6', '7', '(or last', '[d]', 'treatment', 'cycle) [e]', ' 28 days', 'Day', '-28 to -1', '-7 to-1', '1', '1', '1', '1', '1', '1', '1', '1', '1', 'from last', 'study dose', 'Arm', 'Arm', 'TASQ-SC', 'B', 'A', 'only', 'only', 'EORTO QLQ-C30 [t]', 'X', 'X', 'X', 'HCPQ-Treatment Room [u]', 'HCPQ-Drug Preparation', 'Area [u]', 'Bilateral mammogram (or', 'other breast imaging', 'X', 'method per institutional', 'practice) [v]', 'Assessments for breast', 'Per institutional practice or the ACS / ASCO Breast Cancer Survivorship Care Guideline', 'cancer recurrence', '[see Appendix 4]', 'Assessments for non-', 'breast primary cancers', 'Per institutional practice', 'Survival', 'X', 'Arm', 'Arm', 'Arm', 'Arm', 'Arm', 'Arm', 'P+H IV', 'A', 'A', 'A', 'B', 'B', 'B', 'only', 'only', 'only', 'only', 'only', 'only', 'Pertuzumab and', 'Arm', 'Arm', 'Arm', 'Arm', 'Arm', 'Arm', 'B', 'B', 'B', 'A', 'A', 'A', 'trastuzumab FDC SC', 'only', 'only', 'only', 'only', 'only', 'only', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '97 / Protocol MO40628, Version 12']\n\n###\n\n", "completion": "END"}